Coupling low-molecular substances to a modified polysaccharide
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C08B-031/00
C08B-031/02
C08B-031/18
C07K-001/00
C07K-017/00
A61K-031/715
C08B-033/00
C08B-035/00
출원번호
US-0506366
(2003-02-28)
등록번호
US-8466277
(2013-06-18)
우선권정보
DE-102 09 822 (2002-03-06)
국제출원번호
PCT/EP03/02084
(2003-02-28)
§371/§102 date
20050202
(20050202)
국제공개번호
WO03/074088
(2003-09-12)
발명자
/ 주소
Orlando, Michele
Hemberger, Jurgen
Sommermeyer, Klaus
Eichner, Wolfram
Frie, Sven
Lutterbeck, Katharina
Jungheinrich, Cornelius
Scharpf, Roland
출원인 / 주소
Fresenius Kabi Deutschland GmbH
대리인 / 주소
Fish & Richardson P.C.
인용정보
피인용 횟수 :
0인용 특허 :
82
초록▼
The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction betwee
The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular weight substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.
대표청구항▼
1. A conjugate of hydroxyalkylstarch (HAS) and a low molecular weight substance, obtained by a process that comprises selectively coupling (i) the terminal aldehyde group of a HAS molecule, or a functional group derived from this aldehyde group, wherein the functional group derived from the aldehyde
1. A conjugate of hydroxyalkylstarch (HAS) and a low molecular weight substance, obtained by a process that comprises selectively coupling (i) the terminal aldehyde group of a HAS molecule, or a functional group derived from this aldehyde group, wherein the functional group derived from the aldehyde group is one of the functional groups of a bifunctional linker molecule with which the terminal aldehyde group has been reacted, with (ii) a functional group on the low molecular weight substance, which is able to react with the terminal aldehyde group of the HAS molecule or the functional group derived therefrom, wherein the coupling reaction results in a covalent bond between the terminal aldehyde of the HAS molecule or the functional group derived therefrom and the low molecular weight substance functional group, or wherein the coupling reaction is modified by a further reaction to give the abovementioned covalent bond, wherein the low molecular weight substance is an active pharmaceutical ingredient, (a) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is an amino group and the active pharmaceutical ingredient is selected from the group consisting of albuterol, alendronate, amikazin, aminopenicillin, amoxicillin, atenolol, azathioprine, cefaclor, cefadroxil, cefotaxime, ceftazidime, ceftriaxone, cilastatin, cimetidine, ciprofloxacin, clonidine, colistin, cosyntropin, cycloserine, daunorubicin, doxorubicin, desmopressin, dihydroergotamine, dobutamine, dopamine, ephedrine, epinephrine, ε-aminocaproic acid, ergometrine, esmolol, famotidine, flecainide, folic acid, flucytosine, furosemide, ganciclovir, gentamicin, glucagon, hydrazaline, imipenem, isoproterenol, ketamine, liothyronine, LHRH, merpatricin, metaraminol, methyldopa, metoclopramide, metoprolol, mexiletine, mitomycin, neomycin, netilmicin, nimodipine, nystatin, octreotide, oxytocin, pamidronate, pentamidine, phentolamine, phenylephrine, procainamide, procaine, propranolol, ritodrine, sotalol, teicoplanin, terbutaline, thiamine, tiludronate, tolazoline, trimethoprim, tromethamine, vancomycin, vasopressin, and vinblastine,or(b) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is a carboxyl group or activated carboxyl group and the active pharmaceutical ingredient is selected from the group consisting of acetylcysteine, azlocillin, aztreonam, benzylpenicillin, camptothecin, cefamandole, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cephalothin, cilastatin, ciprofloxacin, clavulanic acid, dicloxacillin, epsilonaminocaproic acid, floxacillin, folinic acid, furosemide, fusidic acid, imipemem, indomethacin, ketorolac, liothyronine, melphalan, methyldopa, piperacillin, prostacyclin, prostaglandins, teicoplanin, ticarcillin, and vancomycin,or(c) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is an aliphatic or aryl-OH group and the active pharmaceutical ingredient is selected from the group consisting of albuterol, allopurinol, apomorphine, ceftriaxone, dobutamine, dopamine, doxycycline, edrophonium, isoproterenol, liothyronine, metaraminol, methyldopa, minocycline, paclitaxel, pentazocine, phenylephrine, phentolamine, propofol, rifamycins, ritodrine, taxol, teicoplanin, terbutaline, tetracycline, and vancomycin. 2. The conjugate as claimed in claim 1, wherein the functional group of the low molecular weight substance is one of the functional groups of a bifunctional linker molecule which has been coupled to the low molecular weight substance. 3. The conjugate as claimed in claim 1, wherein the covalent bonding is an amine linkage which is the result of a coupling reaction between the terminal aldehyde group of the HAS molecule and a primary amino group of the low molecular weight substance to form a Schiff's base, and reduction of the Schiff's base to the amine. 4. The conjugate as claimed in claim 1, wherein the HAS molecule has a molecular weight in the range from about 70 to about 1000 kD. 5. The conjugate as claimed in claim 4, wherein the HAS molecule has a molecular weight of about 130 kD. 6. The conjugate as claimed in claim 1, wherein the HAS molecule has a degree of substitution of from about 0.3 to about 0.7. 7. The conjugate as claimed in claim 1, wherein the HAS molecule has a ratio of C2 to C6 substitution of from 8 to 12. 8. The conjugate as claimed in claim 1, wherein the HAS molecule is a hydroxyethylstarch molecule. 9. A pharmaceutical composition comprising an effective amount of a conjugate as claimed in claim 1 and a pharmaceutically acceptable carrier. 10. A conjugate of HAS and a low molecular weight substance, wherein the conjugate comprises at least one covalent bond between: (i) the terminal aldehyde group of the HAS molecule, or a functional group derived from the terminal aldehyde group, wherein the functional group derived from the aldehyde group is one of the functional groups of a bifunctional linker molecule with which the terminal aldehyde group has been reacted, and(ii) a functional group of the low molecular weight substance, wherein the low molecular weight substance is an active pharmaceutical ingredient,(a) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is an amino group and the active pharmaceutical ingredient is selected from the group consisting of albuterol, alendronate, amikazin, aminopenicillin, amoxicillin, atenolol, azathioprine, cefaclor, cefadroxil, cefotaxime, ceftazidime, ceftriaxone, cilastatin, cimetidine, ciprofloxacin, clonidine, colistin, cosyntropin, cycloserine, daunorubicin, doxorubicin, desmopressin, dihydroergotamine, dobutamine, dopamine, ephedrine, epinephrine, ε-aminocaproic acid, ergometrine, esmolol, famotidine, flecainide, folic acid, flucytosine, furosemide, ganciclovir, gentamicin, glucagon, hydrazaline, imipenem, isoproterenol, ketamine, liothyronine, LHRH, merpatricin, metaraminol, methyldopa, metoclopramide, metoprolol, mexiletine, mitomycin, neomycin, netilmicin, nimodipine, nystatin, octreotide, oxytocin, pamidronate, pentamidine, phentolamine, phenylephrine, procainamide, procaine, propranolol, ritodrine, sotalol, teicoplanin, terbutaline, thiamine, tiludronate, tolazoline, trimethoprim, tromethamine, vancomycin, vasopressin, and vinblastine,or(b) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is a carboxyl group or activated carboxyl group and the active pharmaceutical ingredient is selected from the group consisting of acetylcysteine, azlocillin, aztreonam, benzylpenicillin, camptothecin, cefamandole, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cephalothin, cilastatin, ciprofloxacin, clavulanic acid, dicloxacillin, epsilonaminocaproic acid, floxacillin, folinic acid, furosemide, fusidic acid, imipemem, indomethacin, ketorolac, liothyronine, melphalan, methyldopa, piperacillin, prostacyclin, prostaglandins, teicoplanin, ticarcillin, and vancomycin,or(c) wherein the functional group of the active pharmaceutical ingredient involved in the coupling reaction is an aliphatic or aryl-OH group and the active pharmaceutical ingredient is selected from the group consisting of albuterol, allopurinol, apomorphine, ceftriaxone, dobutamine, dopamine, doxycycline, edrophonium, isoproterenol, liothyronine, metaraminol, methyldopa, minocycline, palcitaxel, pentazocine, phenylephrine, phentolamine, propofol, rifamycins, ritodrine, taxol, teicoplanin, terbutaline, tetracycline, and vancomycin. 11. The conjugate of claim 10, wherein the functional group derived from the terminal aldehyde group of the HAS molecule is a functional group of a bifunctional linker coupled to the terminal aldehyde group or functional group derived therefrom. 12. The conjugate of claim 10, wherein the functional group of the low molecular weight substance is a functional group of a bifunctional linker coupled to the low molecular weight substance. 13. The conjugate of claim 10, wherein the HAS molecule has a degree of substitution of from about 0.3 to about 0.7. 14. The conjugate of claim 10, wherein the HAS molecule is a hydroxyethylstarch molecule.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (82)
Cerny Lawrence C. (Utica NY), Acellular resuscitative fluid.
Cuatrecasas ; Pedro ; Parikh ; Indu, Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglio.
Berninger Ronald W. ; Lodge Mark S. ; Tarnowski ; Jr. Stanley Joseph ; Colvin Floyd Warren ; Brinkley John Michael, Aminooxy-containing linker compounds for formation of stably-linked conjugates and methods related thereto.
Stahl Wilhelm (Frankfurt am Main DEX) Ahlers Michael (Mainz DEX) Walch Axel (Frankfurt am Main DEX) Bartnik Eckhart (Wiesbaden DEX) Kretzschmar Gerhard (Eschborn DEX) Grabley Susanne (Koenigstein DEX, Carbohydrate-containing polymers, their preparation and use.
Buysch Hans-Josef (Krefeld DEX) Klausener Alexander (Krefeld DEX) Szablikowski Klaus (Walsrode DEX) Balser Klaus (Walsrode DEX) Wilke Michaela (Schneverdingen DEX), Carbonic acid esters of polysaccharides and a process for their production.
Studier F. William (Stony Brook NY) Davanloo Parichehre (Basel NY CHX) Rosenberg Alan H. (Setauket NY) Moffatt Barbara A. (East Lansing MI) Dunn John J. (Bellport NY), Cloning and expression of the gene for bacteriophage T7 RNA polymerase.
Hedlund Bo E. (New Brighton MN) Hallaway Philip E. (Minneapolis MN) Panter Samuel S. (Minneapolis MN) Eaton John W. (Minneapolis MN), Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid.
Shadle Paula J. (Richmond CA) Koths Kirston E. (El Cerrito CA) Moreland Margaret (Berkeley CA) Katre Nandini (El Cerrito CA), Conjugation of polymer to colony stimulating factor-1.
Sommermeyer Klaus (Rosbach DEX) Cech Franz (Rosbach DEX) Weidler Burghard (Rosbach DEX) Henning Klaus (Usingen DEX), Hydroxylethylstarch (HES) as plasma expander and process for preparing HES.
Dellacherie Edith (Malzeville FRX) Leonard Michle (Neuves-Maisons FRX) Sacco Daniel (Nancy FRX) Vigneron Claude (Nancy FRX), Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses.
Leonard Michle (Vandoeuvre FRX) Dellacherie Edith (Malzeville FRX) Neel Jean M. L. (Villers-Ls-Nancy FRX) Vigneron Claude (Nancy FRX) Labrude Pierre (Laxou FRX), Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses.
Hedlund Bo E. (New Brighton MN) Hallaway Philip E. (Minneapolis MN) Panter Samuel S. (Minneapolis MN) Eaton John W. (Minneapolis MN), Method for the stabilization of deferoxamine to chelate free ions in physiological fluid.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Gustavson Linda M. (19809 - 31st St. ; NE. Seattle WA 98155) Anderson David C. (200 Lassen Dr. San Bruno CA 94066) Morgan ; Jr. Alton C. (803 Driftwood Pl. Edmonds WA 98020), Polymeric carriers for non-covalent drug conjugation.
Vanderhoff, John W.; Lu, Cheng Xun; Lee, Clarence C.; Tsai, Chi-Chun, Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained.
Okada Shigetaka (Nara JPX) Kitahata Sumio (Osaka JPX) Yoshikawa Shigeharu (Okayama JPX) Sugimoto Toshiyuki (Okayama JPX) Sugimoto Kaname (Okayama JPX), Process for the production of branching enzyme, and a method for improving the qualities of food products therewith.
Szablikowski Klaus (Walsrode DEX) Buysch Hans-Josef (Krefeld DEX) Klausener Alexander (Krefeld DEX), Process for the production of polysaccharide carbonates.
Jeannette C. Roberts ; Britta H. Wilmore ; Pamela B. Cassidy ; Pamela K. Dominick ; Megan D. Short, Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof.
Sommermeyer,Klaus; Zander,Norbert; Frank,Ronald; Conradt,Harald, Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments.
Anthony J. Martinez ; Annapurna Pendri ; Richard B. Greenwald ; Yun H. Choe, Terminally-branched polymeric linkers and polymeric conjugates containing the same.
Lees Andrew ; Mond James J.,ILX, Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts.
Lihme Allan O. F. (Birkerd DKX) Boenisch Thomas (Goleta CA), Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.